The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas.
 
Dmitrii Grachev
Employment - BostonGene
 
Danil Ivanov
Employment - BostonGene
 
Vladimir Kushnarev
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
 
Sheila T. Yong
Employment - BostonGene
 
Nikita Kotlov
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - Co-author of 1 BostonGene patent
Travel, Accommodations, Expenses - BostonGene
 
Konstantin Chernyshov
Employment - BostonGene
Patents, Royalties, Other Intellectual Property - BostonGene
Travel, Accommodations, Expenses - BostonGene
 
Alexander Bagaev
Employment - BostonGene
Stock and Other Ownership Interests - BostonGene
Patents, Royalties, Other Intellectual Property - Patents for IP created In BostonGene
 
Nathan Hale Fowler
Employment - BostonGene
Leadership - BostonGene
Stock and Other Ownership Interests - BostonGene
Consulting or Advisory Role - Bayer; Celgene; Novartis; Roche/Genentech; TG Therapeutics; Verastem
Research Funding - Abbvie; BeiGene; Celgene; Gilead Sciences; Novartis; Roche; TG Therapeutics
 
Anthony Paul Conley
Consulting or Advisory Role - AADi; Applied Clinical Intelligence; Bayer; Deciphera; Deciphera; Genentech; Guidepoint Global; Guidepoint Global; InhibRx; Medscape; Nektar; Novartis; OncLive; Schlesinger Associates
Research Funding - Bavarian Nordic (Inst); Chordoma Foundation (Inst); EpicentRx (Inst); Ignyta (Inst); InhibRx (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); MedImmune (Inst); NantHealth (Inst); NCI (Inst)
Travel, Accommodations, Expenses - Genentech
 
Gregory Michael Cote
Honoraria - BioAtla; Gilead Sciences
Consulting or Advisory Role - C4 Therapeutics; Daiichi Sankyo/UCB Japan; Ikena Oncology; Sonata
Research Funding - Bavarian Nordic; Bayer (Inst); BioAtla (Inst); C4 Therapeutics (Inst); Eisai (Inst); Epizyme (Inst); Foghorn Therapeutics (Inst); Ikena Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Macrogenics (Inst); Merck KGaA (Inst); PharmaMar (Inst); Pyxis (Inst); Rain Therapeutics (Inst); Repare Therapeutics (Inst); Servier (Inst); Springworks Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Counterpoint; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma